Rituximab Therapy for Refractory Scleritis Results of a Phase I/II Dose-Ranging, Randomized, Clinical Trial

Grants

Funding Acknowledgements

E. B. S.: Research Supportd-Department of Veterans'AffairsSupported in part by Genentech (San Francisco, CA). The funding organization had no role in the design or conduct of this research. Funded by a Research to Prevent Blindness grant (unrestricted grant to Casey Eye Institute), the Rosenfeld Family Trust (J. T. R.), and the William and Mary Bauman Foundation. The OHSU Uveitis Clinic has received research support from Genentech, Abbott/Abbvie, Bristol-Myers-Squibb, EyeGate, LuxBio, and Novartis.